PSX Company Profiles
What listed companies do, how they make money, key financials and Shariah status, researched by the PSX Investors Zone team.
13 companies
Pharmaceuticals
Abbott Laboratories (Pakistan) Limited
Abbott Laboratories (Pakistan) Limited (PSX: ABOT) is a Pakistani pharmaceutical and healthcare company incorporated in 1948. Its business includes branded generic medicines, nutritional products, diagnostics, diabetes care, hospital products and consumer healthcare products. Explore its financial performance, dividend history, Shariah-screening status and key business risks before conducting further investment research.
Pharmaceuticals
AGP Limited
AGP Limited (AGP) is a Pakistan Stock Exchange-listed pharmaceutical company involved in importing, marketing, exporting, distributing, wholesaling and manufacturing pharmaceutical products. In 2025, it reported standalone sales of approximately Rs. 20.55 billion, profit after tax of Rs. 2.36 billion and EPS of Rs. 8.43. Its portfolio and subsidiaries support its presence across Pakistan’s healthcare market. Investors should examine earnings growth, product demand, regulatory requirements, distribution costs, debt and the latest Shariah screening before making investment decisions.
Pharmaceuticals
BF Biosciences Limited
BF Biosciences Limited (BFBIO) is a Pakistan Stock Exchange-listed pharmaceutical company engaged in developing, manufacturing, marketing and distributing pharmaceutical products. It is an 80:20 joint venture between Ferozsons Laboratories Limited and Argentina's Bagó Group. In FY2026, the company reported revenue of Rs.9.46 billion and profit after tax of Rs.632.13 million, reflecting strong year-on-year growth. BFBIO was classified as Shariah-compliant in the PSX screening effective May 29, 2026. Investors should review its latest financial reports, expansion spending, regulatory developments and current Shariah status before making investment decisions.
Paper & Board — packaging materials
Cherat Packaging Limited
Cherat Packaging Limited (PSX: CPPL) is a Pakistani packaging manufacturer incorporated in 1989. Its business includes paper sacks, polypropylene bags, SOS/carrier bags and flexible packaging materials supplied to industries such as cement, food, beverages, pharmaceuticals and consumer goods. For the financial year ended 30 June 2026, the company reported sales of Rs.15.09 billion, profit after tax of Rs.651.01 million and earnings per share of Rs.13.26. It was classified as Shariah-compliant in the PSX-KMI All Share Islamic Index screening effective 5 June 2026, based on accounts to 31 December 2025. Investors should also note that the official PSX profile displays a Risk Warning Alert relating to continuous regulatory violations and potential trading suspension or delisting. Review the latest regulatory disclosures, financial statements and Shariah screening before making investment decisions.
Pharmaceuticals
Citi Pharma Limited
Citi Pharma Limited (CPHL) is a Pakistan Stock Exchange-listed pharmaceutical manufacturer established in 2012 and listed in 2021. Its principal activities include manufacturing and selling pharmaceutical products, medical chemicals and botanical products. The company’s performance depends on product demand, manufacturing costs, regulatory requirements, raw-material availability, pricing and competition. In FY2026, CPHL reported standalone sales of approximately Rs. 14.00 billion, profit after tax of Rs. 782.60 million and EPS of Rs. 3.43. Investors should review its financial performance, debt, cash flows, valuation, dividend history and latest official Shariah-screening status before making investment decisions.
Pharmaceuticals
Ferozsons Laboratories Limited
Ferozsons Laboratories Limited (PSX: FEROZ) is a Pakistani pharmaceutical company incorporated in 1954 that commenced commercial operations in 1956. Its core business includes importing, manufacturing and selling pharmaceutical products and medical devices. The company also has interests in BF Biosciences Limited, a pharmaceutical business, and Farmacia, a medicine retail and distribution venture. For FY2026, Ferozsons reported standalone revenue of approximately Rs. 15.76 billion, profit after tax of Rs. 650.90 million and EPS of Rs. 14.97. On a consolidated basis, revenue reached Rs. 23.96 billion and profit after tax was approximately Rs. 1.23 billion, with consolidated EPS of Rs. 22.51. The board recommended a final cash dividend of Rs. 5.50 per share for FY2026, subject to shareholder approval at the AGM scheduled for October 28, 2026. Ferozsons appeared as Shariah-compliant in the PSX-KMI All Share Islamic Index screening information effective June 5, 2026, based on December 2025 data. Investors should verify the latest screening status. **Important PSX Risk Warning:** The official PSX company page displays an alert concerning continuous violation of specified listing-regulation clauses and potential trading suspension or delisting. Investors should review the latest official notice and company disclosures before making investment decisions.
Modarabas
First Imrooz Modaraba
First Imrooz Modaraba (PSX: FIMM) is a Pakistan Stock Exchange-listed, multipurpose modaraba formed in 1993 and operational since 1994. Unlike modarabas primarily focused on financial services, it specializes in trading industrial raw materials for industries including paints and coatings, pharmaceuticals, food, agriculture, personal care, household products and textiles. For FY2026, PSX reports sales of approximately Rs. 1.054 billion and total income of Rs. 1.059 billion. The Board approved a final profit distribution of Rs. 10 per certificate for FY2026. FIMM was listed as Shariah-compliant in the PSX-KMI All Share Islamic Index review effective June 5, 2026. Investors should also review the Risk Warning Alert currently displayed on the official PSX company page, which identifies potential suspension or delisting risk.
Chemicals
Ghani Chemical Industries Limited
Ghani Chemical Industries Limited (PSX: GCIL) is a Pakistani manufacturer and supplier of medical and industrial gases. Incorporated in 2015 and listed on the Pakistan Stock Exchange in 2022, the company supplies gases including oxygen, nitrogen, and argon to healthcare institutions and industrial customers across sectors such as steel, engineering, oil and gas, pharmaceuticals, food processing, and manufacturing. For the financial year ended June 30, 2026, GCIL reported standalone net sales of approximately Rs 8.280 billion, profit after tax of Rs 2.861 billion, and EPS of Rs 5.02. Compared with FY2025, net sales increased by approximately 11.4% and profit after tax increased by approximately 43.5%. The board recommended no cash dividend for FY2026. GCIL was listed as Shariah-compliant in the KMI All Share Islamic Index review effective June 5, 2026, with a non-compliant income ratio of 2.40% in that review. PACRA maintained its A long-term and A1 short-term credit ratings with a Positive outlook in May 2026. **Important regulatory consideration:** The PSX company page displays a Risk Warning Alert referring to continuing violations of specified exchange clauses and possible suspension or delisting. Investors should review the current PSX notice and the company's subsequent disclosures before assessing the stock.
Pharmaceuticals
GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited (PSX: GLAXO) is a pharmaceutical company engaged in manufacturing and marketing research-based medicines and other pharmaceutical products in Pakistan. It is part of the global GSK group and operates across therapy areas including anti-infectives, dermatology, analgesics, and vaccines. For the year ended December 31, 2025, the company reported sales of approximately Rs65.90 billion, profit after tax of Rs10.03 billion, and earnings per share of Rs31.48. Its financial performance, product portfolio, manufacturing operations, regulatory environment, and cash-flow position are important factors for fundamental analysis. GLAXO was classified as Shariah-compliant in the PSX KMI All Share screening published in May 2026, based on financial statements available through December 2025. Investors should check subsequent screening updates before making decisions. **Important:** The official PSX company page displays a Risk Warning Alert stating that the company is in continuous violation of specified exchange clauses and carries a risk of trading suspension or delisting. Investors should review the latest PSX disclosures and understand this regulatory risk before evaluating the stock. Sources: [PSX company profile and financials](https://dps.psx.com.pk/company/GLAXO) | [GSK Pakistan](https://pk.gsk.com/en-pk/company/) | [PSX KMI screening notice](https://www.psx.com.pk/psx/files/?file=277899-1.pdf)
Pharmaceuticals
Haleon Pakistan Limited
Haleon Pakistan Limited (PSX: HALEON) is a listed consumer healthcare company manufacturing, marketing and selling over-the-counter health products in Pakistan. Formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited, it became part of the independent Haleon group following the consumer healthcare demerger. Its product portfolio includes well-known brands in pain relief, oral health, respiratory health and vitamins and supplements. For 2025, the company reported revenue of Rs43.106 billion, profit after tax of Rs6.373 billion and EPS of Rs54.45. Its latest reviewed 2026 quarterly results, for the quarter ended June 30, reported revenue of Rs10.072 billion and profit after tax of Rs1.676 billion. Haleon Pakistan was classified as Shariah-compliant in the PSX-KMI All Share Islamic Index recomposition published in May 2026, based on December 2025 financial statements. However, the official PSX profile displays a Risk Warning Alert concerning continuous exchange-rule violations and potential trading suspension or delisting. Investors should verify the latest exchange notices and Shariah screening before making decisions.
Pharmaceuticals
Hoechst Pakistan Limited
Hoechst Pakistan Limited (PSX: HPL) is a Pakistan Stock Exchange-listed pharmaceutical company engaged in manufacturing, selling and trading pharmaceutical and related products. Incorporated in 1967, the company operates from Korangi Industrial Area, Karachi, and reports its financial results on a calendar-year basis. In FY2025, Hoechst Pakistan reported sales of Rs30.929 billion, profit after tax of Rs2.910 billion and EPS of Rs301.67, compared with sales of Rs26.748 billion and profit after tax of Rs1.857 billion in FY2024. For the quarter ended September 30, 2026, it reported sales of Rs7.790 billion, profit after tax of Rs614.346 million and EPS of Rs63.70. HPL was classified as Shariah-compliant in the PSX-KMI All Share Islamic Index recomposition published in May 2026, based on December 2025 financial statements. Investors should monitor quarterly profitability, product and regulatory developments, dividend sustainability and any changes in the company's latest Shariah screening status.
Pharmaceuticals
IBL HealthCare Limited
IBL HealthCare Limited (PSX: IBLHL) is a Pakistani healthcare-products distribution and marketing company incorporated in 1997 and listed on the Pakistan Stock Exchange. Its principal activities include marketing, selling and distributing healthcare and pharmaceutical products across categories including nutrition, sweeteners and beverages, and medical and surgical disposables. The company is a subsidiary of The Searle Company Limited. In FY2026, IBL HealthCare reported revenue of Rs4.607 billion, profit after tax of Rs220.402 million and EPS of Rs2.24, compared with revenue of Rs4.322 billion and profit after tax of Rs208.371 million in FY2025. The board declared no cash dividend for FY2026. IBLHL was classified as Shariah-compliant in the PSX-KMI All Share Islamic Index recomposition published in May 2026, based on December 2025 financial data. Investors should also note that PSX currently displays a Risk Warning Alert concerning potential trading suspension or delisting, making the latest exchange notices essential reading.
Pharmaceuticals
The Searle Company Limited
The Searle Company Limited (PSX: SEARL) is a Pakistani pharmaceutical company engaged in manufacturing pharmaceutical and consumer products. Incorporated in 1965, it operates in Pakistan's healthcare and medicines market. In FY2026, the company reported sales of approximately Rs. 31.64 billion, profit after tax of Rs. 4.00 billion and earnings per share of Rs. 6.81. Investors researching SEARL should assess its earnings recovery, product portfolio, margins, regulatory environment, cash flow, Shariah screening status and the Risk Warning Alert displayed on its PSX profile. Past financial performance does not guarantee future results. Sources: https://dps.psx.com.pk/company/SEARL | https://searlecompany.com/investor-information/